These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 11714865)

  • 1. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos.
    Dai D; Tang J; Rose R; Hodgson E; Bienstock RJ; Mohrenweiser HW; Goldstein JA
    J Pharmacol Exp Ther; 2001 Dec; 299(3):825-31. PubMed ID: 11714865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype.
    Lee SJ; Bell DA; Coulter SJ; Ghanayem B; Goldstein JA
    J Pharmacol Exp Ther; 2005 Apr; 313(1):302-9. PubMed ID: 15634941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defective activity of recombinant cytochromes P450 3A4.2 and 3A4.16 in oxidation of midazolam, nifedipine, and testosterone.
    Miyazaki M; Nakamura K; Fujita Y; Guengerich FP; Horiuchi R; Yamamoto K
    Drug Metab Dispos; 2008 Nov; 36(11):2287-91. PubMed ID: 18669585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations.
    Lamba JK; Lin YS; Thummel K; Daly A; Watkins PB; Strom S; Zhang J; Schuetz EG
    Pharmacogenetics; 2002 Mar; 12(2):121-32. PubMed ID: 11875366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro metabolism of carbofuran by human, mouse, and rat cytochrome P450 and interactions with chlorpyrifos, testosterone, and estradiol.
    Usmani KA; Hodgson E; Rose RL
    Chem Biol Interact; 2004 Dec; 150(3):221-32. PubMed ID: 15560889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and functional characterization of eight CYP3A4 protein variants.
    Eiselt R; Domanski TL; Zibat A; Mueller R; Presecan-Siedel E; Hustert E; Zanger UM; Brockmoller J; Klenk HP; Meyer UA; Khan KK; He YA; Halpert JR; Wojnowski L
    Pharmacogenetics; 2001 Jul; 11(5):447-58. PubMed ID: 11470997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region.
    Westlind A; Löfberg L; Tindberg N; Andersson TB; Ingelman-Sundberg M
    Biochem Biophys Res Commun; 1999 May; 259(1):201-5. PubMed ID: 10334940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity.
    Sata F; Sapone A; Elizondo G; Stocker P; Miller VP; Zheng W; Raunio H; Crespi CL; Gonzalez FJ
    Clin Pharmacol Ther; 2000 Jan; 67(1):48-56. PubMed ID: 10668853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups.
    Lee SJ; Usmani KA; Chanas B; Ghanayem B; Xi T; Hodgson E; Mohrenweiser HW; Goldstein JA
    Pharmacogenetics; 2003 Aug; 13(8):461-72. PubMed ID: 12893984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine (DPPE) a chemopotentiating and cytoprotective agent in clinical trials: interaction with histamine at cytochrome P450 3A4 and other isozymes that metabolize antineoplastic drugs.
    Brandes LJ; Queen GM; LaBella FS
    Cancer Chemother Pharmacol; 2000; 45(4):298-304. PubMed ID: 10755318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations.
    Schirmer M; Toliat MR; Haberl M; Suk A; Kamdem LK; Klein K; Brockmöller J; Nürnberg P; Zanger UM; Wojnowski L
    Pharmacogenet Genomics; 2006 Jan; 16(1):59-71. PubMed ID: 16344723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP3A4 active site volume modification by mutagenesis of leucine 211.
    Fowler SM; Taylor JM; Friedberg T; Wolf CR; Riley RJ
    Drug Metab Dispos; 2002 Apr; 30(4):452-6. PubMed ID: 11901100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The importance of SRS-1 residues in catalytic specificity of human cytochrome P450 3A4.
    Roussel F; Khan KK; Halpert JR
    Arch Biochem Biophys; 2000 Feb; 374(2):269-78. PubMed ID: 10666307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coexpression of genetically engineered fused enzyme between yeast NADPH-P450 reductase and human cytochrome P450 3A4 and human cytochrome b5 in yeast.
    Hayashi K; Sakaki T; Kominami S; Inouye K; Yabusaki Y
    Arch Biochem Biophys; 2000 Sep; 381(1):164-70. PubMed ID: 11019832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular characterization of specifically active recombinant fused enzymes consisting of CYP3A4, NADPH-cytochrome P450 oxidoreductase, and cytochrome b5.
    Inui H; Maeda A; Ohkawa H
    Biochemistry; 2007 Sep; 46(35):10213-21. PubMed ID: 17691855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation analysis of the human CYP3A4 gene 5' regulatory region: population screening using non-radioactive SSCP.
    Hamzeiy H; Vahdati-Mashhadian N; Edwards HJ; Goldfarb PS
    Mutat Res; 2002 Mar; 500(1-2):103-10. PubMed ID: 11890939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of human cytochrome b5 on CYP3A4 activity and stability in vivo.
    Voice MW; Zhang Y; Wolf CR; Burchell B; Friedberg T
    Arch Biochem Biophys; 1999 Jun; 366(1):116-24. PubMed ID: 10334871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism.
    Mei Q; Tang C; Assang C; Lin Y; Slaughter D; Rodrigues AD; Baillie TA; Rushmore TH; Shou M
    J Pharmacol Exp Ther; 1999 Nov; 291(2):749-59. PubMed ID: 10525096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes.
    Murayama N; Imai N; Nakane T; Shimizu M; Yamazaki H
    Biochem Pharmacol; 2007 Jun; 73(12):2020-6. PubMed ID: 17433262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online.
    Walker AH; Jaffe JM; Gunasegaram S; Cummings SA; Huang CS; Chern HD; Olopade OI; Weber BL; Rebbeck TR
    Hum Mutat; 1998; 12(4):289. PubMed ID: 10660343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.